A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Single Ascending Doses of ABBV-701 in Healthy Adult Western and Asian Subjects
Latest Information Update: 06 Mar 2026
At a glance
- Drugs ABBV 701 (Primary) ; ABBV 701 (Primary)
- Indications Unspecified
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- Sponsors AbbVie
Most Recent Events
- 02 Mar 2026 Planned End Date changed from 1 Oct 2026 to 1 Nov 2026.
- 02 Mar 2026 Planned primary completion date changed from 1 Oct 2026 to 1 Nov 2026.
- 02 Mar 2026 Status changed from recruiting to active, no longer recruiting.